Li Dalin, Debbas Philip, Cheng Susan, Braun Jonathan, McGovern Dermot P B, Melmed Gil Y
Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Smidt Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, CA.
medRxiv. 2021 Dec 7:2021.12.05.21266089. doi: 10.1101/2021.12.05.21266089.
Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile after a 3 mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown. We aimed to assess symptomology after a 3 or booster dose of mRNA vaccination in adults with IBD. We surveyed participants of the Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) post-vaccination registry for symptom frequency and severity after a 3 mRNA vaccine dose in an observational cohort study. In total, 524 participants (70% female, mean age 45 years) reported a third dose of mRNA vaccination through October 11, 2021. Overall, 41% reported symptoms after a third dose, with symptoms generally more frequent and more severe among participants younger than 55 years. The most frequent postvaccination symptoms were injection site pain (39%), fatigue or malaise (34%), and headache (23%). These symptoms were all less frequently reported after dose 3 than after dose 2. Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after dose 2 (7.8%). Those with severe symptoms after dose 2 were more likely to have severe symptoms after dose 3. These findings can reassure the IBD patient and provider communities that the likelihood and distribution of symptoms after a third mRNA vaccine dose are generally similar to those after a second dose, and that the frequency of postvaccination symptoms after dose 3 are generally lower than after dose 2.
炎症性肠病（IBD）患者接种新型冠状病毒2型（SARS-CoV-2） 初种疫苗后的症状，其出现频率、严重程度和持续时间通常与普通人群报告的情况相似。在主要为免疫功能低下的IBD人群中，接种3剂mRNA疫苗后的症状特征尚不清楚。我们旨在评估IBD成年患者接种3剂或加强剂量mRNA疫苗后的症状情况。在一项观察性队列研究中，我们对炎症性肠病冠状病毒风险关联与纵向评估（CORALE-IBD）疫苗接种后登记处的参与者进行了调查，以了解接种3剂mRNA疫苗后的症状频率和严重程度。截至2021年10月11日，共有524名参与者（70%为女性，平均年龄45岁）报告接种了第3剂mRNA疫苗。总体而言，41%的参与者在接种第3剂后出现症状，55岁以下参与者的症状通常更频繁、更严重。接种疫苗后最常见的症状是注射部位疼痛（39%）、疲劳或不适（34%）以及头痛（23%）。这些症状在第3剂后报告的频率均低于第2剂后。有8.8%的人报告了胃肠道症状，略高于第2剂后（7.8%）。第2剂后出现严重症状的人在第3剂后更有可能出现严重症状。这些发现可以让IBD患者和医疗服务人员放心，第3剂mRNA疫苗接种后症状出现的可能性和分布情况通常与第2剂后相似，且第3剂接种后疫苗接种后症状的频率通常低于第2剂后。
